Gilead, Galapagos arthritis drug rejected by FDA gets go-ahead from Japanese, European regulators
The European Commission and Japan's Ministry of Health, Labor and Welfare approved filgotinib, marketed under the name Jyseleca, for rheumatoid arthritis. The drug is partnered in Japan with Eisai. The FDA rejected the drug last month.